Why You Need Ocular Therapeutix Inc. (OCUL) On Your Watchlist

Ocular Therapeutix Inc. (NASDAQ:OCUL) saw an upside of 3.70% to close Friday at $10.37 after adding $0.37 on the day. The 5-day average trading volume is 530,140 shares of the company’s common stock. It has gained $10.91 in the past week and touched a new high 1 time within the past 5 days. An average of 703,145 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 756,480.

OCUL’s 1-month performance is -3.89% or -$0.42 on its low of $9.82 reached on 09/16/21. The company’s shares have touched a 52-week low of $7.67 and high of $24.30, with the stock’s rally to the 52-week high happening on 01/11/21. YTD, OCUL has lost -49.90% or -$10.33 and has reached a new high 4 times. However, the current price is down -57.33%% from the 52-week high price.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Insider Transactions

On May 20, 135 days have gone by since the last insider trading activity for Ocular Therapeutix Inc. (OCUL). LINDSTROM RICHARD L MD (Director) most recently sold 10,000 shares at $14.30 per share on May 20. This transaction cost the insider $143,000.

Valuation Metrics

Ocular Therapeutix Inc. (OCUL) has a trailing price-to-earnings (P/E) ratio of 33.74 for the broader industry and 32.48 for the sector, meaning that investors are optimistic about the stock’s future prospects. OCUL stock has a beta of 2.11. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 25.43 while the price-to-book (PB) in the most recent quarter is 9.88.

Ocular Therapeutix Inc.’s quick ratio for the period ended June 29 was 10.00, with the current ratio over the same period at 10.00 meaning that OCUL stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.63, while the total debt to equity was 0.63. In terms of profitability, the gross margin trailing 12 months is 90.30%. The firm’s gross profit as reported stood at $15.32 million against revenue of $17.4 million.

The effectiveness of a company’s management is also important for investors when it comes to determining the potential profitability of the investment. Ocular Therapeutix Inc.’s return on assets over the past 12 months stands at -49.40%. Return on investment over the past year is -50.00%, while its return on equity (ROE) trailing 12 months is -174.70%. In comparison, the average ROE for the broader industry over the past year is -36.91.

Earnings Surprise

For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 86.6% to $11.72 million, while revenue of $7.34 million was 37.37% off the previous quarter. Analysts expected OCUL to announce -$0.21 per share in earnings in its latest quarter, but it posted -$0.11, representing a 47.60% surprise. EBITDA for the quarter stood at more than -$19.62 million. OCUL stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 150.46 million, with total debt at $58.5 million. Shareholders hold equity totaling $76.58 million

Technical Picture

Let’s look briefly at Ocular Therapeutix Inc. (OCUL) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 01 October was 47.63% to suggest the stock is trending Neutral, with historical volatility in this time period at 47.18%.

The stock’s 5-day moving average is $10.37, reflecting a -1.14% or -$0.12 change from its current price. OCUL is currently trading -7.25% above its 20-day SMA, -34.16% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -14.44% and -54.81% respectively.

Stochastic %K and %D was 24.60% and 28.99% and the average true range (ATR) pointed at 0.49. The RSI (14) points at 46.94%, while the 14-day stochastic is at 40.24% with the period’s ATR at 0.51. The stock’s 9-day MACD Oscillator is pointing at -0.29 and -0.26 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for Ocular Therapeutix Inc. (NASDAQ: OCUL), H.C. Wainwright upgraded it to a Buy rating. They previously had a Neutral rating on the stock. Analysts offering their rating for OCUL stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate OCUL as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 6 have offered a “buy” rating.

What is OCUL’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $15.00 and a high of $33.00, with their median price target at $25.00. Looking at these predictions, the average price target given by analysts is for Ocular Therapeutix Inc. (OCUL) stock is $23.43.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

spot_img

Hot Topics

Related Videos

Related Videos

Related Articles

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

592

100% free. stop anytime no spam